No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(-)-3-(4-aminophenyl)-2-methoxypropionic acid |
- |
- |
- |
- |
1件: 97 |
2 |
(r)-3-(1-oxo-propoxy)-4-(n,n,n-trimethyl amonium chloride)-butanoic acid |
Butyric acid |
D05866 |
- |
- |
1件: 97 |
3 |
(s)-(-)-3-(4-aminophenyl)-2-methoxypropionic acid |
- |
- |
- |
- |
1件: 97 |
4 |
(s)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1h-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride |
- |
- |
- |
- |
1件: 97 |
5 |
-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
6 |
0.25 mg rpc1063 |
- |
- |
- |
- |
2件: 96, 97 |
7 |
0.25mg rpc103 |
- |
- |
- |
- |
1件: 97 |
8 |
0.5 mg rpc1063 |
- |
- |
- |
- |
1件: 97 |
9 |
1 mg rpc1063 |
- |
- |
- |
- |
1件: 97 |
10 |
1.0 mg rpc103 |
- |
- |
- |
- |
1件: 97 |
11 |
1.0 mg rpc1063 |
- |
- |
- |
- |
1件: 97 |
12 |
1.remicade |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
13 |
10 mg natura-alpha capsule |
- |
- |
- |
- |
1件: 97 |
14 |
100 mg |
- |
- |
- |
- |
1件: 97 |
15 |
150 mg |
- |
- |
- |
- |
1件: 97 |
16 |
1500mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
17 |
15n2-tofacitinib |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
1件: 97 |
18 |
2 x 10 mg natura-alpha capsules |
- |
- |
- |
- |
1件: 97 |
19 |
2'-fucosyllactose |
- |
- |
- |
- |
2件: 96, 97 |
20 |
2-hydroxybenzoic acid |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
21 |
20 mg |
- |
- |
- |
- |
1件: 97 |
22 |
225mg pf-00547659 |
- |
- |
- |
- |
1件: 97 |
23 |
23-valent polysaccharide pneumococcal vaccine (pneumovax tm) |
- |
- |
- |
- |
2件: 96, 97 |
24 |
250mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
25 |
2l polyethylene glycol/ascorbic acid |
Polyethylene glycol |
D03370 |
- |
- |
1件: 97 |
26 |
331731-18-1 |
- |
- |
- |
- |
2件: 46, 97 |
27 |
40 mg msb11022 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
28 |
42942019 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
29 |
450 mg |
- |
- |
- |
- |
1件: 97 |
30 |
5 asa |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
31 |
5 asa, enemas, suppositories, corticosteroids |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
32 |
5-amino salicylic acid |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
33 |
5-amino salicylic acid (5-asa) |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
34 |
5-amino-2-hydroxybenzoic acid |
Salicylic acid |
D00097 |
- |
- |
1件: 97 |
35 |
5-aminosalicyclic acid |
- |
- |
- |
- |
1件: 97 |
36 |
5-aminosalicylate |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
37 |
5-aminosalicylate (pentasa, ferring) |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
38 |
5-aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
39 |
5-aminosalicylic acid (5-asa) |
Aminosalicylic acid |
D00162 |
- |
- |
1件: 97 |
40 |
5-aminosalicylic acid(5-asa) and/or prednisone |
Aminosalicylic acid |
D00162 |
- |
- |
1件: 97 |
41 |
5-asa |
Mesalazine |
D00377 |
- |
- |
2件: 96, 97 |
42 |
5-asa (5-aminosalicylate) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
43 |
5-asa mmx |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
44 |
5-htp |
- |
- |
- |
- |
2件: 96, 97 |
45 |
50 mg |
- |
- |
- |
- |
1件: 97 |
46 |
500 mg lx1606 qd |
- |
- |
- |
- |
1件: 97 |
47 |
500 mg lx1606 tid |
- |
- |
- |
- |
1件: 97 |
48 |
500mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
49 |
549-0261/f02-01 |
- |
- |
- |
- |
2件: 96, 97 |
50 |
5asa |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
51 |
6 mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
52 |
6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid |
- |
- |
- |
- |
1件: 97 |
53 |
6-mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 97, 164 |
54 |
6-mp |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
55 |
750mg mesalazine pellets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
56 |
75mg pf-00547659 |
- |
- |
- |
- |
1件: 97 |
57 |
[124i]ib pf 06687234 |
- |
- |
- |
- |
1件: 97 |
58 |
[14c]-rpc1063 solution (0.1 mg/ml) for oral administration |
- |
- |
- |
- |
3件: 13, 96, 97 |
59 |
[18f]fspg |
- |
- |
- |
- |
2件: 96, 97 |
60 |
A multistrain probiotic product (dsf) |
- |
- |
- |
- |
1件: 97 |
61 |
A: 1 dosis |
- |
- |
- |
- |
1件: 97 |
62 |
Ab (antibiotics) |
- |
- |
- |
- |
1件: 97 |
63 |
Abalimumab |
- |
- |
- |
- |
1件: 97 |
64 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
65 |
Abatacept (aba) |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
1件: 97 |
66 |
Abbv-006 |
- |
- |
- |
- |
1件: 97 |
67 |
Abbv-066 |
- |
- |
- |
- |
2件: 96, 97 |
68 |
Abbv-323 dose a |
- |
- |
- |
- |
1件: 97 |
69 |
Abbv-323 dose b |
- |
- |
- |
- |
1件: 97 |
70 |
Abgn-168h |
- |
- |
- |
- |
1件: 97 |
71 |
Abi-m201 |
- |
- |
- |
- |
1件: 97 |
72 |
Abt-494 |
- |
- |
- |
- |
3件: 46, 96, 97 |
73 |
Abx464 |
Abx464 |
- |
- |
- |
3件: 46, 96, 97 |
74 |
Abx464 100mg |
Abx464 |
- |
- |
- |
2件: 46, 97 |
75 |
Abx464 25mg |
Abx464 |
- |
- |
- |
1件: 97 |
76 |
Abx464 50mg |
Abx464 |
- |
- |
- |
2件: 46, 97 |
77 |
Accelerated 1 hour-infusion |
- |
- |
- |
- |
2件: 96, 97 |
78 |
Accelerated 30 minutes-infusion |
- |
- |
- |
- |
2件: 96, 97 |
79 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
80 |
Acetic acid |
Acetic acid |
D00010 |
- |
- |
1件: 97 |
81 |
Active group |
- |
- |
- |
- |
1件: 97 |
82 |
Adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
83 |
Adipose tissue-derived mesenchymal stem cells |
- |
- |
- |
- |
1件: 97 |
84 |
Adipose-cord mesenchymal stromal cells (a-mscs) |
- |
- |
- |
- |
1件: 97 |
85 |
Aeb071 |
- |
- |
- |
- |
1件: 97 |
86 |
Ag011 |
- |
- |
- |
- |
1件: 97 |
87 |
Ag011 - capsules |
- |
- |
- |
- |
1件: 97 |
88 |
Ag011 - enema |
- |
- |
- |
- |
1件: 97 |
89 |
Ajg501 |
- |
- |
- |
- |
1件: 97 |
90 |
Ajg511 |
- |
- |
- |
- |
1件: 97 |
91 |
Ajm300 |
- |
- |
- |
- |
1件: 97 |
92 |
Aldesleukin |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
3件: 49, 65, 97 |
93 |
Alicaforsen |
Alicaforsen |
- |
- |
- |
2件: 96, 97 |
94 |
Alkaline phosphatase |
Alkaline phosphatase |
- |
- |
- |
3件: 46, 97, 172 |
95 |
Allopurinol |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
6件: 6, 46, 57, 66, 96, 97 |
96 |
Aloasc |
- |
- |
- |
- |
1件: 97 |
97 |
Aloe |
Aloe vera leaf |
- |
- |
- |
1件: 97 |
98 |
Aloe barbadensis miller |
Aloe vera leaf |
- |
- |
- |
1件: 97 |
99 |
Alth12-1:4 |
- |
- |
- |
- |
1件: 97 |
100 |
Alth12-2:4 |
- |
- |
- |
- |
1件: 97 |
101 |
Amg 181 |
- |
- |
- |
- |
2件: 96, 97 |
102 |
Amgevita 40mg solution for injection |
- |
- |
- |
- |
2件: 96, 97 |
103 |
Aminosalicylic acid |
Aminosalicylic acid |
D00162 |
- |
- |
2件: 96, 97 |
104 |
Amoxicillin |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
6件: 6, 46, 63, 96, 97, 222 |
105 |
Amoxicillin and tetracycline |
Tetracycline |
D00201 |
- |
- |
1件: 97 |
106 |
Amoxicillin, metronidazole and tetracycline |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
1件: 97 |
107 |
And (andrographolide) |
Andrographolide |
- |
- |
- |
1件: 97 |
108 |
Andosan |
- |
- |
- |
- |
2件: 96, 97 |
109 |
Andrographis paniculata |
- |
- |
- |
- |
1件: 97 |
110 |
Andrographis paniculata (ethanol extract) |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
1件: 97 |
111 |
Andrographolide |
Andrographolide |
- |
- |
- |
1件: 97 |
112 |
Anrukinzumab |
Anrukinzumab |
D08857 |
1件: IL13 |
8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
1件: 97 |
113 |
Anti cd3 |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 97 |
114 |
Anti cd3 monoclonal antibody |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 97 |
115 |
Anti tnf therapy including infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
116 |
Anti-cd3 |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
117 |
Anti-cd3 monoclonal antibody |
Muromonab |
D05092 |
3件: CD3D, CD3E, CD3G |
11件: Chagas disease (American trypanosomiasis), Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
2件: 96, 97 |
118 |
Anti-ip-10 antibody |
- |
- |
- |
- |
1件: 97 |
119 |
Anti-madcam antibody |
- |
- |
- |
- |
2件: 96, 97 |
120 |
Anti-tnf discontinuation: physiological saline solution |
- |
- |
- |
- |
2件: 96, 97 |
121 |
Anti-tnf drug |
- |
- |
- |
- |
2件: 96, 97 |
122 |
Anti-tnf therapy |
- |
- |
- |
- |
3件: 46, 96, 97 |
123 |
Anti-tnf: infliximab (infusion) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
124 |
Anti-tnf:adalimumab (subcutaneus) |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
125 |
Antibiotic cocktail |
- |
- |
- |
- |
1件: 97 |
126 |
Aodg (apigenin-7-o-glucuronide) |
Apigenin |
- |
- |
- |
1件: 97 |
127 |
Apd334 |
- |
- |
- |
- |
4件: 93, 96, 97, 269 |
128 |
Apigenin |
Apigenin |
- |
- |
- |
1件: 97 |
129 |
Apixaban |
Apixaban |
D03213 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 96, 97 |
130 |
Apixaban 2.5 milligram |
Apixaban |
D03213 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 96, 97 |
131 |
Apremilast |
Apremilast |
D08860 |
4件: PDE4A, PDE4B, PDE4C, PDE4D |
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
5件: 46, 50, 56, 97, 271 |
132 |
Apriso 0.375g er cap |
- |
- |
- |
- |
1件: 97 |
133 |
Apriso 375 mg extended-release capsules |
- |
- |
- |
- |
1件: 97 |
134 |
Apvo210 |
- |
- |
- |
- |
1件: 97 |
135 |
Aquamin® |
- |
- |
- |
- |
1件: 97 |
136 |
Asacol |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
137 |
Asacol (mesalamine) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
138 |
Asacol (mesalamine) delayed-release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
139 |
Asacol 400 mg |
- |
- |
- |
- |
1件: 97 |
140 |
Asacol 400 mg (mesalamine) |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
141 |
Asacol 400 mg tablet |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
142 |
Asacol 800 mg (mesalamine) |
Mesalazine, Mesalazine |
D00377 |
- |
- |
1件: 97 |
143 |
Asacol 800 mg tablet |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
144 |
Asacol delayed release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
145 |
Asacol delayed-release tablets |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
146 |
Asacol tablet |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
147 |
Asacol® |
- |
- |
- |
- |
1件: 97 |
148 |
Asacol® 400 mg |
- |
- |
- |
- |
1件: 97 |
149 |
Ascorbic acid |
Ascorbic acid |
D00018 |
- |
- |
2件: 10, 97 |
150 |
Asp3291 |
- |
- |
- |
- |
1件: 97 |
151 |
Aspergillus oryzae |
Aspergillus oryzae |
- |
- |
- |
1件: 97 |
152 |
Ast-120 |
- |
- |
- |
- |
2件: 96, 97 |
153 |
Atl-2502 |
- |
- |
- |
- |
1件: 97 |
154 |
Avonex |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 13, 97 |
155 |
Avx 470 |
- |
- |
- |
- |
1件: 97 |
156 |
Azafor 50mg |
- |
- |
- |
- |
1件: 97 |
157 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
158 |
Azathioprine (aza) |
Azathioprine |
D00238, D03033 |
- |
- |
2件: 19, 97 |
159 |
Azathioprine (aza) or 6-mercaptopurine (6-mp) |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
160 |
Azathioprine and allopurinol |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 97 |
161 |
Azathioprine or 6-mercaptopurine |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 96, 97 |
162 |
Azatioprina |
Azathioprine |
D00238, D03033 |
- |
- |
3件: 13, 96, 97 |
163 |
B: 2 dosis |
- |
- |
- |
- |
1件: 97 |
164 |
Bacteriotherapy |
- |
- |
- |
- |
2件: 96, 97 |
165 |
Balsalazide |
Balsalazide |
D02715, D07488 |
- |
- |
1件: 97 |
166 |
Balsalazide disodium |
Balsalazide |
D02715, D07488 |
- |
- |
1件: 97 |
167 |
Baminercept |
Baminercept |
D08866 |
1件: LTB |
3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 53, 97 |
168 |
Bascial prescription plus or minus herbs depend on symptoms |
- |
- |
- |
- |
1件: 97 |
169 |
Basiliximab |
Basiliximab |
D03058 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
6件: 2, 50, 65, 97, 222, 228 |
170 |
Bbt-401-1s, multiple doses |
- |
- |
- |
- |
1件: 97 |
171 |
Bbt-401-1s, single dose |
- |
- |
- |
- |
1件: 97 |
172 |
Beclometasone dipropionate |
Beclomethasone dipropionate |
D00689, D07495 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
173 |
Beclomethasone dipropionate |
Beclomethasone dipropionate |
D00689, D07495 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 97, 98 |
174 |
Beclomethasone diproprionate |
- |
- |
- |
- |
1件: 97 |
175 |
Berberine |
Berberine |
D00092 |
- |
- |
1件: 97 |
176 |
Berberine chloride |
Berberine |
D00092 |
- |
- |
1件: 97 |
177 |
Bertilimumab |
- |
- |
- |
- |
2件: 97, 162 |
178 |
Beta-1,3/1,6-d-glucan |
- |
- |
- |
- |
1件: 97 |
179 |
Bg9418 (interferon beta-1a) |
Human interferon beta |
- |
- |
- |
2件: 13, 97 |
180 |
Bg9924 |
- |
- |
- |
- |
2件: 46, 97 |
181 |
Bi 655130 |
- |
- |
- |
- |
3件: 37, 96, 97 |
182 |
Biap |
- |
- |
- |
- |
2件: 46, 97 |
183 |
Bifidobacterium infantis |
Bifidobacterium longum infantis |
- |
- |
- |
2件: 96, 97 |
184 |
Bifidobacterium infantis 35624 |
Bifidobacterium longum infantis |
- |
- |
- |
2件: 96, 97 |
185 |
Bimekizumab |
Bimekizumab |
D11550 |
2件: IL17A, IL17F |
5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
3件: 46, 97, 271 |
186 |
Bio-enhanced curcumin soft gelatin capsule |
Curcumin |
- |
- |
- |
1件: 97 |
187 |
Biologically active human fecal microbiota |
- |
- |
- |
- |
1件: 97 |
188 |
Biopsies |
- |
- |
- |
- |
1件: 97 |
189 |
Biosimilar |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
190 |
Biosimilar infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
191 |
Bitter candytuft fresh plant extract |
- |
- |
- |
- |
1件: 97 |
192 |
Bitterschleifenblume-ganzpflanze 1,5ml/10ml |
- |
- |
- |
- |
1件: 97 |
193 |
Bl-7040 |
- |
- |
- |
- |
1件: 97 |
194 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
195 |
Blood samples |
- |
- |
- |
- |
8件: 13, 41, 46, 51, 61, 97, 227, 271 |
196 |
Bms-188667 |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
6件: 46, 49, 65, 96, 97, 271 |
197 |
Bms-986165 |
- |
- |
- |
- |
3件: 49, 96, 97 |
198 |
Bms-986166 |
- |
- |
- |
- |
1件: 97 |
199 |
Bms-986184 |
- |
- |
- |
- |
1件: 97 |
200 |
Boulardii |
- |
- |
- |
- |
2件: 96, 97 |
201 |
Bovine intestinal alkaline phosphatase (biap) |
Alkaline phosphatase |
- |
- |
- |
1件: 97 |
202 |
Bovine-calf alkaline phosphatase (biap) |
Alkaline phosphatase |
- |
- |
- |
1件: 97 |
203 |
Bovine-calf alkaline phosphatase biap |
Alkaline phosphatase |
- |
- |
- |
1件: 97 |
204 |
Brazikumab |
- |
- |
- |
- |
2件: 96, 97 |
205 |
Bt-11 (1000 mg) |
- |
- |
- |
- |
1件: 97 |
206 |
Bt-11 (500 mg) |
- |
- |
- |
- |
1件: 97 |
207 |
Bt-11 active |
- |
- |
- |
- |
2件: 96, 97 |
208 |
Budenofalk 2mg rectal foam |
- |
- |
- |
- |
1件: 97 |
209 |
Budenofalk 3mg |
- |
- |
- |
- |
2件: 93, 97 |
210 |
Budenofalk rectal foam |
- |
- |
- |
- |
1件: 97 |
211 |
Budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 |
212 |
Budesonide (6 mg) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
213 |
Budesonide (9 mg) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
214 |
Budesonide 6 mg capsules, hard (bux-pvii prototype) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
215 |
Budesonide 9 mg capsules, hard (bux-pv) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
216 |
Budesonide 9 mg capsules, hard (bux-pvii prototype) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
217 |
Budesonide mmx 6 mg tablet |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
218 |
Budesonide mmx® |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
219 |
Budesonide mmx® 6 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
220 |
Budesonide mmx® 9 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
221 |
Budesonide-mmx |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
222 |
Budesonide-mmx® |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
223 |
Budesonide-mmx® 6 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
224 |
Budesonide-mmx® 9 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
225 |
Budesonide-mmx™ |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
226 |
Butanoic acid |
Butyric acid |
D05866 |
- |
- |
3件: 34, 51, 97 |
227 |
Caffeine |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 2, 6, 46, 78, 96, 97 |
228 |
Calcitonin nasal spray (salmon) |
- |
- |
- |
- |
2件: 96, 97 |
229 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
230 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
231 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
232 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
233 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
7件: 6, 46, 85, 86, 96, 97, 298 |
234 |
Carbon dioxide |
Carbon dioxide |
D00004 |
- |
- |
1件: 97 |
235 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
8件: 5, 13, 58, 96, 97, 265, 298, 316 |
236 |
Carrageenan |
- |
- |
- |
- |
1件: 97 |
237 |
Carvi extractum fluidum |
- |
- |
- |
- |
1件: 97 |
238 |
Casein |
Casein |
- |
- |
- |
1件: 97 |
239 |
Casein glycomacropeptide (cgmp) |
Casein |
- |
- |
- |
1件: 97 |
240 |
Cat-354 |
- |
- |
- |
- |
1件: 97 |
241 |
Catridecacog |
Catridecacog |
D10532 |
- |
- |
2件: 97, 288 |
242 |
Cb-01-02 |
- |
- |
- |
- |
1件: 97 |
243 |
Cb-01-05-mmx |
- |
- |
- |
- |
1件: 97 |
244 |
Ceftriaxone |
Ceftriaxone |
D00924, D07659 |
- |
- |
3件: 2, 6, 97 |
245 |
Cefuroxime |
Cefuroxime |
D00262, D00914, D00915, D03431 |
- |
- |
1件: 97 |
246 |
Certolizumab pegol |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 37, 46, 96, 97, 226, 271 |
247 |
Cgmp |
Cyclic gmp |
- |
- |
- |
1件: 97 |
248 |
Cgmp protein |
Cyclic gmp |
- |
- |
- |
1件: 97 |
249 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
250 |
Chlorogenic acid |
Chlorogenic acid |
- |
- |
- |
1件: 97 |
251 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
252 |
Ciclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
13件: 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 |
253 |
Cimzia |
Certolizumab pegol |
D03441 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 46, 96, 97, 271 |
254 |
Ciprofloxacin |
Ciprofloxacin |
D00186, D02216 |
- |
- |
5件: 2, 60, 96, 97, 299 |
255 |
Cla (chlorogenic acid) |
Chlorogenic acid |
- |
- |
- |
1件: 97 |
256 |
Clarithromycin |
Clarithromycin |
D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
257 |
Clipper |
- |
- |
- |
- |
1件: 97 |
258 |
Clotrimazole |
Clotrimazole |
D00282 |
- |
- |
1件: 97 |
259 |
Cnto148 |
- |
- |
- |
- |
2件: 46, 97 |
260 |
Coamoxiclav |
- |
- |
- |
- |
1件: 97 |
261 |
Cobitolimod |
Cobitolimod |
- |
- |
- |
1件: 97 |
262 |
Coffee coal |
- |
- |
- |
- |
1件: 97 |
263 |
Colal-pred |
- |
- |
- |
- |
1件: 97 |
264 |
Colal-pred® |
- |
- |
- |
- |
1件: 97 |
265 |
Coltect |
- |
- |
- |
- |
1件: 97 |
266 |
Combination oral budesonide and rectal hydrocortisone |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
267 |
Corticosteroid |
- |
- |
- |
- |
10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
268 |
Corticosteroids |
- |
- |
- |
- |
9件: 41, 46, 49, 64, 97, 164, 220, 296, 300 |
269 |
Corticosteroids only |
- |
- |
- |
- |
1件: 97 |
270 |
Corticosteroids then mesalamine |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
271 |
Cortimentmmx 9 mg |
- |
- |
- |
- |
1件: 97 |
272 |
Cosmofer |
- |
- |
- |
- |
2件: 96, 97 |
273 |
Cosmofer 50mg/ml solution for infusion or injection |
- |
- |
- |
- |
2件: 96, 97 |
274 |
Cotrimoxazole |
- |
- |
- |
- |
2件: 85, 97 |
275 |
Cp- 690 550 |
- |
- |
- |
- |
1件: 97 |
276 |
Cp-690,500 5 mg |
- |
- |
- |
- |
1件: 97 |
277 |
Cp-690,550 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
278 |
Cp-690,550 10 mg |
- |
- |
- |
- |
1件: 97 |
279 |
Cp-690,550-10 |
- |
- |
- |
- |
3件: 46, 96, 97 |
280 |
Cp690,550 |
- |
- |
- |
- |
2件: 46, 97 |
281 |
Cs (corticosteroids) only |
- |
- |
- |
- |
1件: 97 |
282 |
Ct-p13 |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
283 |
Curcumin |
Curcumin |
- |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
284 |
Cyclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
16件: 14, 38, 39, 49, 53, 56, 60, 62, 63, 97, 113, 164, 222, 223, 274, 326 |
285 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
286 |
Cyclosporine (usan) |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 97 |
287 |
Cyclosporine vs infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
288 |
Cycol |
- |
- |
- |
- |
1件: 97 |
289 |
Cycol™ |
- |
- |
- |
- |
1件: 97 |
290 |
D-proline |
Proline |
D00035 |
- |
- |
1件: 97 |
291 |
Daclizumab |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
7件: 13, 56, 60, 65, 97, 283, 284 |
292 |
Dacortin |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 46, 97 |
293 |
Dand (14-deoxyandrographolide) |
- |
- |
- |
- |
1件: 97 |
294 |
Ddand (14-deoxy-11,12-didehydroandrographolide) |
- |
- |
- |
- |
1件: 97 |
295 |
Decortin |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
5件: 46, 96, 97, 113, 145 |
296 |
Decortin h 1 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
297 |
Decortin h 10mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
298 |
Decortin h 20mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
299 |
Decortin h 50 mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
300 |
Decortin h 5mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
301 |
Dekristol |
- |
- |
- |
- |
2件: 13, 97 |
302 |
Deligoparin |
- |
- |
- |
- |
1件: 97 |
303 |
Delmitide acetate |
Acetate |
- |
- |
- |
1件: 97 |
304 |
Deltacortene |
- |
- |
- |
- |
1件: 97 |
305 |
Dersalazine |
Dersalazine |
- |
- |
- |
1件: 97 |
306 |
Dersalazine sodium |
Dersalazine |
- |
- |
- |
1件: 97 |
307 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
308 |
Dexamethasone 21-phosphate |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
309 |
Dextran |
Dextran |
D00060 |
- |
- |
5件: 2, 62, 79, 96, 97 |
310 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
311 |
Dims0150 |
- |
- |
- |
- |
1件: 97 |
312 |
Doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
313 |
E. coli nissle |
- |
- |
- |
- |
1件: 97 |
314 |
Ecologic 825 |
- |
- |
- |
- |
1件: 97 |
315 |
Egf enema |
- |
- |
- |
- |
1件: 97 |
316 |
Eicosapentaenoic acid |
Icosapent |
D08061 |
- |
- |
5件: 49, 96, 97, 296, 297 |
317 |
Emea/h/c/000481 |
- |
- |
- |
- |
1件: 97 |
318 |
Encapsulated faecal microbiota |
- |
- |
- |
- |
1件: 97 |
319 |
Encapsulated faecal microbiota filtrate |
- |
- |
- |
- |
1件: 97 |
320 |
Entecavir |
Entecavir |
D04008, D07896 |
- |
- |
5件: 46, 56, 96, 97, 271 |
321 |
Entocort ec® 3 mg |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
322 |
Entocort® cr |
- |
- |
- |
- |
1件: 97 |
323 |
Entyvio |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
2件: 96, 97 |
324 |
Entyvio 300mg |
Vedolizumab |
D08083 |
2件: ITGA4, ITGB7 |
15件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection |
1件: 97 |
325 |
Epaxal berna (virosomal hepatitis a vaccine) |
Hepatitis a vaccine |
- |
- |
- |
2件: 96, 97 |
326 |
Epidermal growth factor |
- |
- |
- |
- |
1件: 97 |
327 |
Epidermal growth factor enema |
- |
- |
- |
- |
1件: 97 |
328 |
Ergocalciferol |
Ergocalciferol |
D00187 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
5件: 46, 84, 96, 97, 299 |
329 |
Ethanol |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
3件: 97, 279, 280 |
330 |
Etrasimod |
Etrasimod |
D10930 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 97 |
331 |
Etrolizumab |
Etrolizumab |
D09901 |
1件: ITGB7 |
11件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer |
2件: 96, 97 |
332 |
Etrozulimab |
- |
- |
- |
- |
1件: 97 |
333 |
Eubacterial spores, purified suspension, encapsulated |
- |
- |
- |
- |
1件: 97 |
334 |
Exposure to golimumab |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
335 |
Faecal microbiota transplantation |
- |
- |
- |
- |
2件: 96, 97 |
336 |
Fe 999301 |
- |
- |
- |
- |
2件: 96, 97 |
337 |
Fecal microbial transplant |
- |
- |
- |
- |
2件: 96, 97 |
338 |
Fecal microbial transplantation |
- |
- |
- |
- |
2件: 96, 97 |
339 |
Fecal microbiota |
- |
- |
- |
- |
2件: 13, 97 |
340 |
Fecal microbiota enema |
- |
- |
- |
- |
1件: 97 |
341 |
Fecal microbiota transplant |
- |
- |
- |
- |
2件: 96, 97 |
342 |
Fecal microbiota transplantation |
- |
- |
- |
- |
5件: 2, 66, 94, 96, 97 |
343 |
Fecal microbiota transplantation (fmt) |
- |
- |
- |
- |
2件: 96, 97 |
344 |
Fecal microbiota transplantation (fmt), openbiome |
- |
- |
- |
- |
1件: 97 |
345 |
Ferric carboxymaltose |
Ferric carboxymaltose |
D08920 |
- |
- |
4件: 86, 96, 97, 299 |
346 |
Ferrous sulphate |
- |
- |
- |
- |
2件: 96, 97 |
347 |
Filgotinib |
Filgotinib |
D10871 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
6件: 46, 53, 96, 97, 222, 271 |
348 |
Fitc-adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
349 |
Flagyl |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
2件: 96, 97 |
350 |
Flaxseed lignan-enriched complex (flc) |
- |
- |
- |
- |
1件: 97 |
351 |
Flixabi |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
352 |
Fluorescein |
Fluorescein |
D01261, D02024 |
- |
- |
2件: 19, 97 |
353 |
Flupentixol |
Flupentixol |
D01044 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 97 |
354 |
Fmt infusions |
- |
- |
- |
- |
1件: 97 |
355 |
Fosfomycin |
Fosfomycin |
D00925, D02187, D02188, D04253 |
- |
- |
2件: 96, 97 |
356 |
Fp-110 |
- |
- |
- |
- |
1件: 97 |
357 |
Fp-cya-050 |
- |
- |
- |
- |
1件: 97 |
358 |
Fp-cya-053 |
- |
- |
- |
- |
1件: 97 |
359 |
Freeze-dried black raspberry powder |
Raspberry |
- |
- |
- |
1件: 97 |
360 |
G321605 |
- |
- |
- |
- |
3件: 85, 96, 97 |
361 |
Ganciclovir |
Ganciclovir |
D00333, D04301 |
- |
- |
3件: 28, 60, 97 |
362 |
Gastro-resistant phosphatidylcholine granules |
- |
- |
- |
- |
1件: 97 |
363 |
Gb004 |
- |
- |
- |
- |
1件: 97 |
364 |
Ged-0301 |
- |
- |
- |
- |
2件: 96, 97 |
365 |
Ged-0507-34-levo |
- |
- |
- |
- |
1件: 97 |
366 |
Ged-0507-34-levo 160 mg |
- |
- |
- |
- |
1件: 97 |
367 |
Ged-0507-34-levo 80 mg |
- |
- |
- |
- |
1件: 97 |
368 |
Ged0507 |
- |
- |
- |
- |
1件: 97 |
369 |
Gelatin |
Gelatin |
D00115, D06892 |
- |
- |
4件: 47, 78, 97, 269 |
370 |
Gi-270384 |
- |
- |
- |
- |
1件: 97 |
371 |
Glpg0974 |
Glpg0974 |
- |
- |
- |
1件: 97 |
372 |
Glpg1205 |
Glpg1205 |
- |
- |
- |
3件: 85, 96, 97 |
373 |
Glutamine |
L-glutamine |
D00015 |
- |
- |
6件: 87, 96, 97, 113, 245, 299 |
374 |
Glycyrrhiza |
Glycyrrhiza glabra |
- |
- |
- |
1件: 97 |
375 |
Glycyrrhiza glabra |
Glycyrrhiza glabra |
- |
- |
- |
1件: 97 |
376 |
Glycyrrhiza glabra root |
Glycyrrhiza glabra |
- |
- |
- |
1件: 97 |
377 |
Golimumab |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
5件: 46, 84, 96, 97, 271 |
378 |
Golimumab (glm) |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
379 |
Golimumab (optimization) |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
380 |
Golimumab 1 mg per kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
381 |
Golimumab 100 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 97 |
382 |
Golimumab 2 mg per kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
383 |
Golimumab 200 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
384 |
Golimumab 4 mg per kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
385 |
Golimumab 400 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
386 |
Golimumab 50 mg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 46, 97 |
387 |
Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
388 |
Golimumab dose 1 |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
389 |
Golimumab dose 2 |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
390 |
Golimumab prefilled syringe |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
391 |
Golimumab treatment optimization. |
Golimumab |
D04358 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
392 |
Gralise |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
2件: 97, 226 |
393 |
Granulated mesalamine |
Mesalazine |
D00377 |
- |
- |
1件: 97 |
394 |
Grapefruit |
Grapefruit |
- |
- |
- |
5件: 6, 46, 50, 83, 97 |
395 |
Group 1- control diet |
- |
- |
- |
- |
1件: 97 |
396 |
Group 2- ucd diet |
- |
- |
- |
- |
1件: 97 |
397 |
Gs-4875 |
- |
- |
- |
- |
1件: 97 |
398 |
Gs-5745 |
- |
- |
- |
- |
2件: 46, 97 |
399 |
Gs-5745 iv |
- |
- |
- |
- |
1件: 97 |
400 |
Gs-5745 sc |
- |
- |
- |
- |
1件: 97 |
401 |
Gs-6034 |
- |
- |
- |
- |
3件: 46, 96, 97 |
402 |
Gsk1399686 |
- |
- |
- |
- |
1件: 97 |
403 |
Gsk1605786 |
- |
- |
- |
- |
2件: 96, 97 |
404 |
Gsk1605786a |
- |
- |
- |
- |
2件: 96, 97 |
405 |
Gsk2586184 400mg |
- |
- |
- |
- |
1件: 97 |
406 |
Gsk2831781 |
- |
- |
- |
- |
1件: 97 |
407 |
Gsk2982772 |
- |
- |
- |
- |
2件: 46, 97 |
408 |
Gsk2982772a, where a denotes the free base |
- |
- |
- |
- |
2件: 46, 97 |
409 |
Guaiazulene |
Guaiazulen |
- |
- |
- |
1件: 97 |
410 |
Guselkumab |
Guselkumab |
D10438 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
3件: 37, 96, 97 |
411 |
Guselkumab dose 1 |
Guselkumab |
D10438 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
1件: 97 |
412 |
Guselkumab dose 2 |
Guselkumab |
D10438 |
1件: IL23A |
9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
1件: 97 |
413 |
Gwp42003 |
- |
- |
- |
- |
1件: 97 |
414 |
He3286 |
He3286 |
- |
- |
- |
2件: 46, 97 |
415 |
Hemay007 |
- |
- |
- |
- |
1件: 97 |
416 |
Hepatitis a vaccine |
Hepatitis a vaccine |
- |
- |
- |
3件: 46, 96, 97 |
417 |
Herbal treatment (sa100) |
- |
- |
- |
- |
1件: 97 |
418 |
Hextend |
Hydroxyethyl starch |
D03335 |
- |
- |
2件: 96, 97 |
419 |
Hgd40 |
- |
- |
- |
- |
1件: 97 |
420 |
Hgs1025 |
- |
- |
- |
- |
1件: 97 |
421 |
High dose |
- |
- |
- |
- |
1件: 97 |
422 |
Hmpl-004 |
- |
- |
- |
- |
1件: 97 |
423 |
Hmpl-004 tablet |
- |
- |
- |
- |
1件: 97 |
424 |
Hmpl004-6599 |
- |
- |
- |
- |
2件: 96, 97 |
425 |
Hum291 |
- |
- |
- |
- |
2件: 96, 97 |
426 |
Human anti-tnf-alpha monoclonal antibody |
- |
- |
- |
- |
2件: 46, 97 |
427 |
Humira |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 46, 84, 96, 97, 269, 271 |
428 |
Humira 40 mg solution for injection in pre-filled syringe |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
429 |
Humira 40 mg solution for injection in pre-filled syringes |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
430 |
Humira 40 mg/0.8 ml solution for injection for paediatric use |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
431 |
Humira 40mg solution for injection |
- |
- |
- |
- |
2件: 96, 97 |
432 |
Humira® |
- |
- |
- |
- |
4件: 46, 96, 97, 271 |
433 |
Hyaluronate |
Hyaluronic acid |
D08043 |
- |
- |
2件: 53, 97 |
434 |
Hydrocortisone |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
435 |
Hydrocortisone sodium succinate |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 97 |
436 |
Hydrogen |
Hydrogen |
- |
- |
- |
5件: 5, 6, 17, 97, 226 |
437 |
Hydroxide |
Hydroxide ion |
- |
- |
- |
4件: 46, 96, 97, 284 |
438 |
Ibd98-m |
- |
- |
- |
- |
1件: 97 |
439 |
Ibd98-m delayed-release capsules |
- |
- |
- |
- |
1件: 97 |
440 |
Iberogast n |
- |
- |
- |
- |
1件: 97 |
441 |
Im90838 |
- |
- |
- |
- |
1件: 97 |
442 |
Impact |
Topramezone |
- |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
443 |
Imu-838 |
- |
- |
- |
- |
1件: 97 |
444 |
Imuran |
Azathioprine |
D00238, D03033 |
- |
- |
2件: 96, 97 |
445 |
Imurek 25mg filmtabletten |
- |
- |
- |
- |
1件: 97 |
446 |
Imurek 50mg filmtabletten |
- |
- |
- |
- |
1件: 97 |
447 |
Imurel |
- |
- |
- |
- |
2件: 96, 97 |
448 |
Inflectra |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
449 |
Infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
22件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
450 |
Infliximab (ifx) |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 97 |
451 |
Infliximab 10 mg/kg |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 46, 96, 97 |
452 |
Infliximab 5 mg/kg |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
2件: 96, 97 |
453 |
Infliximab [infliximab biosimilar 3] |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
4件: 37, 46, 96, 97 |
454 |
Infliximab and adalimumab |
Adalimumab, Infliximab |
D02597, D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B |